| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 14 Jul 2026 | 14 Jul 2026 |
| Outcome of the Meeting of the Board of Directors of Welcure Drugs & Pharmaceuticals Ltd held on today i.e. Tuesday, 14th July, 2026. | ||
| Board Meeting | 19 Jun 2026 | 19 Jun 2026 |
| Outcome of the Meeting of the Board of Directors of Welcure Drugs & Pharmaceuticals Limited held on Today i.e. Friday, 19th June, 2026 | ||
| Board Meeting | 29 May 2026 | 22 May 2026 |
| Welcure Drugs & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 inter alia to consider and approve Audited Financial Results for the quarter/year ended 31st March 2026 along with Statement of Assets and Liabilities and Cash Flow Statement for the year ended 31st March 2026. | ||
| Board Meeting | 12 Feb 2026 | 7 Feb 2026 |
| Welcure Drugs & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2026 inter alia to consider and approve Un-audited Financial Results for the quarter & Nine month ended December 31 2025 along with Limited review report (Financial Results). Outcome of the Meeting of the Board of Directors of Welcure Drugs & Pharmaceuticals Limited held on Today i.e. Thursday, 12th February, 2026 Outcome of the Meeting of the Board of Directors of Welcure Drugs & Pharmaceuticals Limited held on Today i.e. Thursday, 12th February, 2026 (As Per BSE Announcement Dated on 12.02.2026) | ||
| Board Meeting | 6 Dec 2025 | 1 Dec 2025 |
| Welcure Drugs & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/12/2025 inter alia to consider and approve various matters in connection with the Rights Issue Postponment of the meeting of the Right Issue Committe of the Welcure Drugs and Pharmaceuticals Limited which was to be held today i.e Monday,December 05,2025 In furtherance to our earlier letter dated December 01, 2025, this is to inform you that the meeting of the Rights Issue Committee of the Company was scheduled to be held on December 05, 2025, inter alia, to consider and approve fixing record date, Issue price, entitlement ratio and other terms and conditions related to right issue, in relation to the Rights Issue as approved by the Rights Issue Committee of the Company in their meeting held on December 01,2025, As the in-principle approval from the Stock Exchange w.r.t. above said Rights Issue is under process as of now, the meeting of the Rights Issue Committee which was scheduled to be held on December 05, 2025 is now postponed and will be held within next working day post receipt of in-principle approval letter from the stock exchange for the abovementioned rights issue. (As Per BSE Announcement Dated on 05.12.2025) Outcome of the Meeting of the Board of Directors of Welcure Drugs and Pharmaceuticals Limited held today i.e. Saturday, December 06, 2025 (As per BSE Announcement dated on: 06.12.2025) | ||
| Board Meeting | 1 Dec 2025 | 24 Nov 2025 |
| Welcure Drugs & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/11/2025 inter alia to consider and approve Intimation of Board Meeting to be held on Thursday November 272025. Welcure Drugs & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/12/2025 ,inter alia, to consider and approve To augment the financial resources of the Company via funds raising by way of issue of equity shares/convertible instruments/other securities through preferential allotment, right issue, QIPs, ADR GDR, FCCB or any other method or combination thereof, in one or more trenches (As per BSE Announcement dated on: 27.11.2025) Outcome of the Meeting of the Board of Directors of Welcure Drugs And Pharmaceuticals Limited held today i.e. Monday, December 01, 2025 (As per BSE Announcement dated on: 01.12.2025) | ||
| Board Meeting | 13 Nov 2025 | 8 Nov 2025 |
| Welcure Drugs & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2025 inter alia to consider and approve the Un-audited Financial Results for the quarter and half year ended September 30 2025 along with Limited review report (Financial Results). Outcome of the meeting of the Board of Directors of Welcure Drugs & Pharmaceuticals Limited held on Today i.e Thursday,13th November 2025. Results-Unaudited Financial Statements For The Quarter And Half Year Ended 30th September 2025. (As Per BSE Announcement Dated on:13.11.2025) | ||
| Board Meeting | 17 Oct 2025 | 17 Oct 2025 |
| Outcome of the Board Meeting-Allotment of Bonus Shares | ||
| Board Meeting | 7 Oct 2025 | 7 Oct 2025 |
| Outcome of Board Meeting held on 07 October, 2025 of Welcure Pharmaceuticlas Limited. | ||
| Board Meeting | 27 Sep 2025 | 4 Sep 2025 |
| Welcure Drugs & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/09/2025 inter alia to consider and approve To take on record and deliberate upon the Letter of Intent (LOI) received from Telexcell Trade PTE LTD Singapore for a proposed acquisition of up to 25% equity stake in Welcure Drugs & Pharmaceuticals Ltd. at an indicative price of Rs. 20 per share (a substantial premium over the prevailing market price). We hereby further inform you that due to non availability of directors , the said meeting of the Board of Directors of the Company has been postponed and is re-scheduled to be held on Saturday , 27th September 2025. (As Per Bse Announcement dated on 25/09/2025) Outcome of the Board Meeting (As Per Bse Announcement dated on 27/09/2025) | ||
In addition, a 10:1 stock split has been cleared, dividing one equity share of ₹10 each into 10 shares of ₹1 each.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
